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Abstract 
 
 
The foundation of the treatment of heart failure with reduced ejection fraction 
(HFREF) is a number of pharmacotherapies that have been shown to reduce 
morbidity and mortality in large randomized multinational clinical trials. These 
include ACE inhibitors, angiotensin receptor blockers, beta-blockers, 
mineralocorticoid receptor antagonists and more recently, a combined 
angiotensin receptor blocker neprilysin inhibitor, sacubitril/valsartan. In select 
cases digoxin, ivabradine and hydralazine with isosorbide dinitrate have a role to 
play in the treatment of HFREF. On this foundation other more advanced 
treatments such as implantable cardioverter defibrillators (ICDs) and cardiac 
resynchronization therapy (CRT) are recommended in guidelines for the 
treatment of HFREF (i.e. an ejection fraction of  40%) and for a select few there 
remains the option of mechanical circulatory support and cardiac transplantation. 
The efficacy of pharmacotherapy does not vary by age and each of these therapies 
should be considered in all patients, irrespective of age. Other factors such as co-
morbidities like renal dysfunction may limit the use of some of these drugs in the 
elderly. Decision making with regards to device therapy is more complex; the 
likelihood of competing non-cardiovascular causes of death and life expectancy 
need to be considered. Despite multiple treatment options for HFREF, the options 
for heart failure with preserved ejection fraction (HFPEF) are limited. In the 
absence of robust outcomes data from a large randomized trial, a 
mineralocorticoid receptor antagonist is a reasonable therapy to reduce the risk 
of hospitalization for HF in HFPEF. 
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Key points 
 
Heart failure with reduced ejection fraction is treated with a number of 
pharmacotherapies that reduce morbidity and mortality regardless of age 
 
Older patients have more comorbidities and may be more likely to develop side 
effects such as hypotension but these side effects can be managed 
 
Heart failure with preserved ejection fraction may be more common in the elderly 
but as yet no therapies have been proven to reduce morbidity and mortality  
 
   
4 
 
1. Introduction 
With advances in the understanding of the pathophysiology of heart failure (HF) 
there have been major advances in the treatment of HF and particularly heart 
failure with reduced ejection fraction (HFREF), i.e. patients with an ejection 
fraction of  40%. Less progress has been made with heart failure with preserved 
ejection fraction (HFPEF- patients with an ejection fraction of > 50%), a form of 
HF for which there are few effective therapies. Despite improvements in both 
pharmacotherapy and device therapy for HF it remains a major cause of morbidity 
and mortality in the elderly. Although the average age of patients with HF is 77 
years1, early landmark clinical trials were designed with age related exclusion 
criteria2,3. While the narrow inclusion and exclusion criteria improve the internal 
validity of the trials, the external validity is consequently limited and clinicians 
must extrapolate the results to populations underrepresented or not studied in 
the trials such as the elderly. 
 
Delivery of treatments recommended by the guidelines, be those drugs or devices, 
is complex and frequently limited by comorbidities, limited physiological reserve, 
altered drug metabolism and the side effects of the treatment. Importantly with 
respect to devices, the potential benefit over the expected remaining years of life 
must be carefully considered. In this review we will focus on the management of 
HF in the older population. We will review the pharmacological therapies that are 
recommended for the treatment of HF in the major international guidelines. We 
will also discuss the issues surrounding selection of patients for device therapy, 
mechanical circulatory support and cardiac transplantation.  
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2. Heart failure in the elderly 
Heart Failure (HF) is one of the major cardiovascular causes of mortality and 
morbidity worldwide. It is predominantly a disease of the elderly with the 
incidence rising after the age of 60 and peaking around the age of 75 years1. Due 
to the aging population, the incidence is increasing and with longer survival due 
to more effective therapies being used, prevalence is also rising1. Furthermore, the 
burden of comorbidity is rising with 87% of patients having at least three other 
comorbidities1, but declines in the very elderly presumable due to survivor bias4.    
 
While in young patients, HF is often labelled as idiopathic, with a dilated 
cardiomyopathy, in the elderly, hypertension and ischemia tend to be the 
predominant etiologies in those with HFREF5. The normal process of ageing also 
causes progressive changes in cardiac structure and function, leading to 
diminished chronotropic and ionotropic responses, myocyte hypertrophy, 
increased intracardiac and filling pressures, and increased afterload.6  
Consequently, HFPEF is more common in the elderly4. Age-associated myocardial 
and vascular wall stiffness may lead to increased filling pressure in a stiff ventricle, 
resulting in pulmonary oedema6. Coexisting comorbidities common in the elderly 
e.g. atrial fibrillation, have potential to trigger acute decompensation in a heart 
with limited cardiac reserve. Coupled with this, older patients are also more likely 
to suffer from other comorbidities such as renal disease, diabetes, chronic lung 
disease and atrial fibrillation, directly and indirectly contributing to the 
myocardial damage, and adding to the complexity of HF.  
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3. Pharmacological treatment of heart failure with reduced ejection 
fraction 
Elderly patients tend to be under-represented in landmark clinical trials of 
therapies currently recommended for the treatment of HF in the guidelines, with 
the mean age being in the 60s (Figure 1).  Additionally, pharmacological treatment 
in elderly patients with HF is frequently limited by comorbidities such as renal 
dysfunction or hypotension. Elderly patients are also more likely to take multiple 
medications, and polypharmacy is associated with increased risk of drug 
interactions and adverse side effects. Although the incidence of side effects varies 
by age, the methods to deal with these do not differ in older compared to younger 
patients and the same principles apply. We would suggest following the 
recommendations in the guidelines with regards to  dealing with side effects of 
the major classes of pharmacotherapy for HF.7 While diuretics are recommended 
for all with signs and symptoms of congestion, other medications recommended 
by guidelines aim to improve morbidity and mortality8,9.  
 
3.1 ACE inhibitors and angiotensin receptor blockers  
The first major breakthrough in the treatment of HFREF came with the finding 
that angiotensin converting enzyme (ACE) inhibitors improved mortality in 
patients with HFREF3,10. The guidelines recommend that all patients with HFREF 
are commenced on an ACE inhibitor8,9. Although there have not been age specific 
analyses of the two main trials that underpin the use of ACE inhibitors, a meta-
analysis, including these two trials and a number of other smaller trials, has shown 
that the efficacy of ACE inhibitors is similar across age groups (Figure 2)11. ACE 
inhibitors improve mortality, and in particular in the elderly, reduce 
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hospitalizations for HF. Angiotensin receptor blockers (ARBs) are an alternative 
to ACE inhibitors in those who cannot tolerate ACE inhibitor8,9. In the Candesartan 
in Heart failure Assessment of Reduction in Mortality and morbidity trial 
(CHARM), the ARB candesartan was similarly effective across the age range in 
patients who could not tolerate an ACE inhibitor in the CHARM-Alternative arm of 
the program12,13. The efficacy of these drugs in the elderly with HFREF is not in 
question given the vast number of patients studied in multiple trials with no 
evidence of any age by treatment interaction. ACE inhibitors and ARBs can cause 
renal dysfunction, hyperkalaemia and hypotension. As older patients tend to have 
poorer renal function and often have issue with low blood pressure, these side 
effects can be more pronounced in the elderly. However, with careful monitoring 
of fluid status (ensuring that the patient is not dry), consideration of other 
therapies that may be causing renal dysfunction or hypotension, these issues can 
be overcome.  
 
3.2 Beta-blockers 
Beta-blockers reduce mortality and morbidity in symptomatic patients with HF 
and current guidelines recommend combination of ACE inhibitors and beta-
blocker as soon as diagnosis of HFREF is made8,9. The major clinical trials that have 
demonstrated the benefit of beta-blockers have been conducted in relatively 
young populations by current standards. However, in contrast to ACE inhibitors 
and ARBs, beta-blockers have been specifically tested in an elderly population in 
the SENIORS trials. The Study of the Effects of Nebivolol Intervention on Outcomes 
and Rehospitalisation in Seniors with Heart Failure study (SENIORS) included 
only patients at the age of 70 or above14. Use of beta-blocker nebivolol, when 
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compared to placebo, was associated with 14% reduction in all cause mortality 
and hospitalization (hazard ratio [HR] 0.86 95% confidence interval [CI] 0.74-
0.99, p= 0.039)26. This was mainly driven by the reduction in hospitalizations and 
not mortality, which was not reduced by nebivolol (HR 0.88, 95% CI 0.71–1.08; p= 
0.21). In recognition of the higher prevalence of HFPEF in the elderly, the SENIORS 
investigators enrolled patients with HFPEF and HFREF15, however only 35% had 
ejection fraction (EF) of > 35%, therefore despite there being no interaction 
between EF and the efficacy of nebivolol, the small number of patients with EF of 
≥ 40% has meant that this therapy is not considered for the treatment of HFPEF 
by the guidelines. SENIORS did however provide valuable information on the 
safety and tolerability of beta-blockers in the elderly. As expected, there was more 
bradycardia and hypotension compared to placebo in the nebivolol group but 
drug discontinuation rates and dose achieved were similar in the beta-blocker and 
placebo groups15. Finally, a comparison of the tolerability of bisoprolol and 
carvedilol in the those >65 years of age, confirmed that these drugs can be used 
and up titrated in this age group16.   
 
 
3.3 Mineralocorticoid receptor antagonists  
The mineralocorticoid receptor antagonists (MRA) spironolactone and 
eplerenone have been tested in two large randomized trials in patients with 
HFREF. Spironolactone was tested in the Randomized ALdactone Evaluation 
Study (RALES) in a population with New York Heart Association Class (NYHA) 
class III and IV HFREF17. Spironolactone reduced the risk of death in all ages 
(Figure 2). The MRA eplerenone was similarly effective in patients in NYHA class 
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II (Figure 2) 18. MRAs, as with ACE inhibitors and ARBs may cause renal 
dysfunction and hyperkalaemia, though they can be managed in the same way. 
Currently MRAs are indicated in patients who are receiving an ACE inhibitor or an 
ARB plus a beta-blocker and still remain symptomatic (NYHA class II or higher)8,9. 
 
 
3.4 Sacubitril/valsartan 
Sacubitril/valsartan is the first in class of the angiotensin receptor neprylisin 
inhibitors (ARNI). This drug is an ARB (valsartan) combined with a neprilysin 
inhibitor (sacubitril). The aim of the drug is to both inhibit the renin-angiotensin-
aldosterone system with valsartan and augment the natriuretic peptides through 
neprilysin inhibition. As such, it should not be prescribed at the same time as an 
ACE inhibitor or an ARB, and before commencing it patients must be off their ACE 
inhibitor for 36 hours. In the Prospective Comparison of ARNI With ACEI to 
Determine Impact on Global Mortality and Morbidity in Heart Failure 
(PARADIGM-HF) trial sacubitril/valsartan was superior to the ACE inhibitor 
enalapril in reducing cardiovascular (CV) death or HF hospitalizations, and all-
cause mortality19. The mean age of patients was 64 years, however nearly 1 in 5 
patients (18.6%) were aged 75 years or older20. The beneficial effect of 
sacubitril/valsartan was consistent across the spectrum of age for all of the 
endpoints studied, including all-cause mortality (Figure 2)20. The major guidelines 
differ slightly in their interpretation of the trial with the European guidelines 
recommending that an ARNI should be initiated in those who are still symptomatic 
despite an ACE inhibitor or an ARB, a beta-blocker and a MRA while the US 
guidelines are more lenient, allowing it to be used in place of an ACE inhibitor or 
an ARB earlier on in the treatment of HFREF. Sacubitril/valsartan is similar to all 
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other inhibitors of the renin-angiotensin-aldosterone system in that it can cause 
hypotension, renal impairment and hyperkalaemia. However, renal dysfunction 
and severe hyperkalaemia are less common with sacubitril/valsartan than 
enalapril and their incidence is no different across the different age groups20. 
Hypotension was a more frequent side effect and more common with 
sacubitril/valsartan than enalapril, but was not more common in the elderly 
(Figure 3)20. Finally there has been some concern that there is a theoretical risk 
that as neprilysin breaks down amyloid-ß peptides that inhibition of neprilysin 
may increase the risk of Alzheimer’s type dementia. However, in a retrospective 
analysis of PARADIGM-HF the rates of reported dementia were no different to a 
number of other trials of medications for heart failure including ARBs, statins and 
direct renin inhibitors.21  
 
3.5 Ivabradine 
The If channel inhibitor ivabradine is used for the treatment of HFREF when the 
patient is in sinus rhythm and either cannot take a beta-blocker (for example due 
to a contraindication such as asthma or bradycardia) or a heart rate of >70 bpm 
despite maximal tolerated dose of beta-blockers. This is on the basis of the Systolic 
Heart failure treatment with the If inhibitor ivabradine Trial (SHIFT)22 that 
demonstrated that ivabradine reduced the composite endpoint of CV death or HF 
hospitalization (although this was mainly through a reduction in HF 
hospitalizations). In an analysis of age groups the authors found no difference in 
the efficacy of ivabradine by age23.  
 
3.6 Digoxin 
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Digoxin has been used for the treatment of HF for thousands of years. The Digitalis 
Investigation Group (DIG) study examined the efficacy of digoxin in patients with 
HFREF and in the ancillary study, those with HFPEF24. Digoxin failed to reduce all 
cause mortality (the primary endpoint) but did reduce the secondary endpoints 
of HF mortality or HF hospitalization, HF hospitalization and all cause 
hospitalizations, and these effects were the same across all ages25.  
 
3.7 Hydralazine and isosorbide dinitrate 
The combination of hydralazine and isosorbide dinitrate has been studied in 
randomized trials26,27. While in the era prior to ACE inhibitors the combination 
was beneficial26, when tested against an ACE inhibitor it failed to improve 
outcomes27. However, the subgroup of patients of African descent did appear to 
gain benefit and in the subsequent African-American Heart Failure Trial (A-
HeFT)28, the combination reduced the primary endpoint of all cause death or HF 
hospitalization. This is thought to be because patients of African descent are less 
responsive to ACE inhibitors due to lower levels of activation of the renin-
angiotensin-aldosterone system. As such hydralazine and isosorbide dinitrate 
remain an option for those unable to take or tolerate an ACE inhibitor, an ARB or 
an ARNI8,9.  
 
4. Device and surgical therapy in HFREF 
4.1 Implantable cardioverter defibrillators and cardiac resynchronization therapy 
While the foundation of treatment of HFREF remains pharmacotherapy, in select 
patients implantable cardioverter defibrillators (ICDs) and cardiac 
resynchronization therapy (CRT) are indicated. However, the use of these device 
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therapies in the elderly is complex. Briefly, ICDs are indicated in a primary 
prevention setting if the patient is symptomatic (NYHA class II-III) with reduced 
EF (≤ 35%) despite 3 months of treatment with optimal medical therapy (OMT)8,9. 
An important additional criterion is that patients should have good functional 
status and should be expected to survive for more than 12 months. This is to 
ensure that the benefits of ICDs are likely to be realized. This can therefore often 
be a barrier to elderly patients. In the setting of secondary prevention ICDs are 
recommended in patients who have recovered from a ventricular arrhythmia, and 
again, who are expected to survive for more than 12 months and have good 
functional status8,9.  
 
Data on primary prevention in the elderly is limited and conflicting29–31. While 
many of the trials showed significant reduction in mortality in comparison to 
medical therapy alone, they predominantly included younger patients. The 
decision to implant an ICD in the elderly includes taking account of likely benefit, 
potential harms (both of the procedure and then the device itself which can fire 
inappropriately) and cost has been reviewed elsewhere32. While the use of ICDs 
in patients with an ischemic aetiology, which is more common in the elderly, is 
less controversial, their use in non-ischemic aetiology of HF is difficult33. Certainly 
the risk/benefit ratio in the whole population, and in particular the elderly, is 
questionable given contemporary rates of sudden death with modern 
pharmacotherapy34,35.  
 
4.2 Cardiac resynchronization therapy (CRT)  
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Cardiac resynchronization therapy (CRT) has been shown to improve quality of 
life, and reduce morbidity and mortality in selected patients with HF. Current 
guidelines recommend CRT in patients with EF ≤ 35%, wide QRS (≥ 130 ms) who 
remain symptomatic (NYHA II-IV) despite OMT8,9. Similar to the trials of medical 
therapies, trials of CRT have tended to include younger patients, though 
subsequent analyses have not shown any difference in efficacy by age36–38.  As with 
pharmacotherapy, the incidence of adverse events following ICD or CRT 
implantation such as pocket infection or haematoma formation is higher in elderly 
patients39. In addition to considering efficacy in the elderly, side effects and 
dealing with side effects of device implantation must be taken into account during 
the decision making process.  
 
4.3 Coronary artery bypass grafting 
In patients with coronary artery disease and HFREF, over a 10 year follow up, 
coronary artery bypass grafting was superior to optimal medical therapy and 
therefore is recommended in the guidelines as a therapeutic option for these 
patients40. However, much like ICDs and CRT, the benefit of surgery must be 
considered in light of potential life expectancy (the benefit takes a number of years 
to become apparent) and the competing risk of non-cardiovascular causes of 
death. As such the efficacy of coronary artery bypass grafting appears to be greater 
in younger patients41.  
 
4.4 Valve surgery and interventions 
In selected patients valve interventions such as surgical valve replacement or 
repair may be indicated in patients with heart failure due to valvular disease and 
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in those patients in whom valve disease is worsening their heart failure7,42.  The 
percutaneous treatment of aortic stenosis has become widespread and may be the 
favoured option in the elderly with more comorbidity who are unable to undergo 
surgical valve repair or replacement. More recently percutaneous techniques for 
the treatment of mitral valve regurgitation have shown promise in clinical trials 
although the mean age of enrolled patients remains relatively young43 
 
5.  Cardiac Transplantation and Mechanical Circulatory Support 
Left ventricular assist devices (LVADs) and cardiac transplantation are important 
therapies for advanced HF. Although their availability remains limited to 
specialized centers, the worldwide number of LVAD implants is increasing. While 
some centers have strict age related criteria for LVAD implantation, the literature 
on outcomes in the elderly remains inconclusive and rates of use after the age of 
65 years are low with data derived mainly from registries44. Similarly for cardiac 
transplantation age is not a contraindication but advancing age is an incremental 
risk factor. As a result, few patients in the UK have been transplanted above the 
age of 65 years although worldwide older patients do receive transplants45. The 
use of cardiac transplantation and LVADs in the elderly is a topic of much debate 
as the potential benefit of the therapies again must be weighed with their highly 
invasive nature and high incidence of serious side effects.46 
 
6. Heart failure with preserve ejection fraction (HFPEF) 
This review has tended to focus on the patients with HFREF, primarily because 
much of the evidence base is in this group. HFPEF is also challenging to diagnose 
correctly and patients are often older and have more comorbidities.47 However, in 
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older age groups the proportion of patients with HFPEF is higher, reaching 50% 
in some series. This group is particularly problematic as there are no clinical trials 
that have demonstrated a benefit of any one therapy in this group. ACE 
inhibitors48, ARBs49,50, MRAs51 and ivabradine52 have all been tested in this group, 
a trial of sacubitril/valsartan in HFPEF is ongoing53. The best current evidence 
comes from the Treatment of Preserved Cardiac Function Heart Failure with an 
Aldosterone Antagonist (TOPCAT) study51, where the MRA spironolactone was 
compared to placebo in patients with HF and EF of ≥45%. The trial was conducted 
in North America, Russia and Georgia, and there was doubt as to the diagnosis and 
adherence to therapy in Russia and Georgia centres. However, in the North 
American patients there was a reduction in HF hospitalization with 
spironolactone. In the absence of any other therapy that alters outcomes, the use 
of spironolactone in this group of patients would seem reasonable as is 
recommended in the guidelines9.  
 
7. Summary 
The management of HFREF and HFPEF in the elderly follows that of patients of 
any age. The pharmacotherapies that are recommended in the guidelines on the 
treatment of HF are also indicated in the elderly and are similarly efficacious in 
this population. Although age per se is not a contraindication to any device or 
surgical treatment for HF, decision making about these therapies is more difficult. 
There should be careful consideration of the potential benefits to the patient, in 
terms of potential gain in life expectancy,  before a decision is made.     
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Table. Guideline recommended therapies for the treatment of symptomatic 
(NYHA class II-IV) heart failure with reduced ejection fraction. Therapies are 
added sequentially if the patient remains symptomatic.7,9,54 
 
Step 1 - First line therapy  Comments 
ACE Inhibitors (or ARB in those 
intolerant of ACE inhibitors 
 
ARBs can be used in those intolerant of 
ACE inhibitors because of side effects 
such as cough 
Beta blockers 
 
 
Step 2 - Second line therapy – 
ongoing symptoms NYHA class II-IV 
 
 
Mineralocorticoid receptor 
antagonists 
 
 
Step 3 - Third line therapy – ongoing 
symptoms NYHA class II-IV 
 
 
Ivabradine (heart rate >=70bpm) 
 
Can be used with a betablocker if there 
is inadequate heart rate control and the 
patient is in sinus rhythm  
Sacubitril/valsartan  
 
Not to be prescribed with an ACE inhibitor 
or ARB. ACE inhibirors should be stopped 
36 hours prior to intiation of 
sacubitril/valsartan 
Isosorbide dinitrate/Hydralazine 
 
 
Digoxin 
 
 
Step 3 - Device therapy  
Implantable cardioverter 
defibrillator (ICD) 
At any time a patient with an ejection fraction 
<=35% may be eligible for an ICD is they have 
a primary prevention indication  
 
Cardiac resynchronization therapy 
(CRT) 
CRT is recommended if the patient 
remains symptomatic with a reduced 
ejection fraction despite optimal medical 
therapy with an ACE inhibitor or ARB, 
betablocker and MRA. CRT is 
recommended if the QRS  duration is ≥ 
130 msec and left bundle branch block is 
present (in sinus rhythm) and can be 
considered if QRS ≥ 130 msec with non-
LBBB (in a sinus rhythm) or in patients 
in atrial fibrillation  
Step 4 - Cardiac transplantation/ 
LVAD 
 
Reserved for select populations after 
extensive workup in a specialist centre  
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Figure 1. Mean age of participants in clinical trials of pharmacotherapies that are recommended in guidelines for the treatment of heart 
failure with reduced ejection fraction and that have been shown to improve morbidity and mortality2,12,56–61,14,18,19,22,24,26,28,55.  
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Figure 2. Efficacy of therapies that have been shown to reduce all cause mortality according to age patients with heart failure and a 
reduced ejection fraction.11,17–19,62  
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Figure 3. Safety profile of sacubitril/valsartan compared to enalapril according 
to age. P for interaction for all comparisons >0.05. 20 
 
